MedTrace Logo

Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i

NCT06975371 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1415

Last updated 2025-10-07

No results posted yet for this study

Summary

This study aims to assess the treatment patterns and real-world outcomes of HR+/HER- metastatic breast cancer patients who have progressed on 1L ET + CDK4/6i and started a second line (2L) treatment within a real-world cohort in the United States Flatiron Health Database.

Conditions

  • Advanced/Metastatic HER2-negative Breast Cancer

Interventions

OTHER

No drug

No study drug was administered in this non-interventional study.

Sponsors & Collaborators

Principal Investigators

  • Director · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-14
Primary Completion
2025-05-08
Completion
2025-08-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06975371 on ClinicalTrials.gov